What Is Metabolic Syndrome?

Metabolic syndrome is not a single disease but a constellation of five interrelated metabolic abnormalities. By the widely accepted ATP III / National Cholesterol Education Program criteria, you meet the threshold for metabolic syndrome when you have any three of the following five criteria simultaneously:

• Abdominal obesity: Waist circumference >40 inches (men) or >35 inches (women)
• High triglycerides: ≥150 mg/dL (or on medication to treat elevated triglycerides)
• Low HDL cholesterol: <40 mg/dL in men or <50 mg/dL in women
• High blood pressure: ≥130/85 mmHg (or on antihypertensive medication)
• Elevated fasting glucose: ≥100 mg/dL (or on medication to treat elevated glucose)

Having two criteria is concerning but sub-threshold. Having all five dramatically amplifies risk. The central metabolic abnormality tying these criteria together is insulin resistance — the root from which the others typically grow.

Why Visceral Fat Is the Danger

Not all fat is metabolically equivalent. Subcutaneous fat — the fat under your skin that you can pinch — is relatively benign. Visceral fat, which accumulates around internal organs (liver, pancreas, intestines, heart), is highly metabolically active and inflammatory. It secretes adipokines, free fatty acids, and inflammatory cytokines that directly impair insulin signaling, raise blood pressure, increase triglyceride production by the liver, and lower HDL.

This is why waist circumference is a more meaningful health metric than BMI. A person can have a "normal" BMI but carry dangerous amounts of visceral fat — a phenotype sometimes called TOFI (thin outside, fat inside). Imaging studies show that visceral fat volume predicts cardiovascular events independently of total body weight.

The good news: visceral fat is also the most responsive to intervention. GLP-1 and GIP/GLP-1 agonists disproportionately reduce visceral fat compared to subcutaneous fat — one reason their cardiovascular benefits appear to exceed what the scale weight change alone would predict.

The Cardiovascular and Metabolic Stakes

Adults with metabolic syndrome have:

• 5x greater risk of developing type 2 diabetes
• 3x greater risk of heart attack or stroke compared to adults without metabolic syndrome
• Doubled risk of dying from cardiovascular disease
• Significantly elevated risk of non-alcoholic fatty liver disease (NAFLD), which can progress to cirrhosis
• Elevated risk of certain cancers, including colorectal and breast cancer

These risks are multiplicative, not additive — having all five criteria is dramatically worse than having one. The urgency of addressing metabolic syndrome early cannot be overstated; intervening before frank diabetes or established cardiovascular disease is when reversal is most achievable.

The Treatment Hierarchy

Treatment of metabolic syndrome follows a logical escalation. The goal is to address the root cause — insulin resistance and visceral adiposity — rather than treating each criterion in isolation with separate medications.

Metabolic Syndrome Criterion	Target Value	First-Line Treatment	Pharmacological Option
Waist Circumference (Men)	<40 inches	Caloric restriction + resistance training	GLP-1 / GIP-GLP-1 agonist
Waist Circumference (Women)	<35 inches	Caloric restriction + resistance training	GLP-1 / GIP-GLP-1 agonist
Fasting Triglycerides	<150 mg/dL	Low-carb diet, omega-3 fatty acids	Fibrates, GLP-1 agonist
HDL Cholesterol	>40 (M) / >50 (F) mg/dL	Exercise, stop smoking, reduce refined carbs	Niacin (limited use)
Blood Pressure	<130/85 mmHg	DASH diet, sodium restriction, exercise	ACE inhibitor, ARB, or CCB
Fasting Glucose	<100 mg/dL	Low glycemic diet, weight loss	Metformin, GLP-1 agonist

Semaglutide's Impact: The SCALE Trial

The SCALE trial and subsequent cardiovascular outcomes data (SELECT trial) have established semaglutide as one of the most powerful available tools for metabolic syndrome reversal. In the SCALE Obesity and Prediabetes trial, patients treated with semaglutide for 104 weeks saw 85% of metabolic syndrome criteria resolve compared to 34% in the placebo group. The SELECT trial — which enrolled 17,604 patients with obesity and established cardiovascular disease — showed semaglutide reduced major adverse cardiovascular events (MACE) by 20%, an outcome that goes far beyond simple weight reduction.

Tirzepatide (Zepbound/Mounjaro) data shows even larger improvements in insulin sensitivity, triglycerides, blood pressure, and waist circumference than semaglutide alone, driven by its additional GIP receptor activity. For patients with full metabolic syndrome, tirzepatide's comprehensive metabolic effects make it a particularly compelling option.

Metformin: The Undervalued Foundation

Before GLP-1 agonists dominated the conversation, metformin was the cornerstone of metabolic syndrome pharmacotherapy. It remains highly relevant — particularly for patients with prediabetes or insulin resistance who either cannot afford GLP-1 agonists or are not yet candidates. Metformin directly reduces hepatic glucose production, improves insulin sensitivity, and has emerging evidence for anti-inflammatory and even anti-aging effects (the TAME trial is investigating metformin's effects on longevity).

For many patients, a combination of metformin plus a GLP-1 agonist provides complementary mechanisms and better overall metabolic control than either alone.

Biomarkers to Track (Beyond Your Annual Physical)

Standard annual physicals often miss early metabolic syndrome. The following biomarkers provide a more complete picture of insulin resistance and cardiovascular risk:

• HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): Calculated from fasting glucose and fasting insulin. Values above 2.0 suggest insulin resistance; above 3.0 is significant. Rarely ordered on standard panels.
• Fasting insulin: Should be measured alongside fasting glucose. Can be elevated years before glucose rises — an early warning sign.
• Triglyceride/HDL ratio: A ratio above 3.5 (in US units) is a strong surrogate marker for insulin resistance and small, dense LDL particles (the most atherogenic type).
• ApoB: More accurate than LDL-C for cardiovascular risk stratification. Elevated in metabolic syndrome even when calculated LDL appears normal.
• hsCRP: High-sensitivity C-reactive protein measures systemic inflammation — often elevated in metabolic syndrome and predictive of cardiovascular events.
• Waist-to-height ratio: Should be below 0.5. Simple, free, and highly predictive of visceral fat burden.